Chronic hepatitis D at a standstill: where do we go from here?
about
Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected HepatocyteHepatitis delta: epidemiology, diagnosis and management 36 years after discoveryCell Culture Models for the Investigation of Hepatitis B and D Virus InfectionHepatitis D virus infection, replication and cross-talk with the hepatitis B virus.Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting PolypeptideA Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.Hepatitis D Virus: A Call to Screening.Modification of Three Amino Acids in Sodium Taurocholate Cotransporting Polypeptide Renders Mice Susceptible to Infection with Hepatitis D Virus In Vivo.A novel toolbox for the in vitro assay of hepatitis D virus infection.Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions.Therapy of Delta Hepatitis.The adventure of delta.Hepatitis B virus receptors and molecular drug targets.Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential.Hepatitis delta: virological and clinical aspects.Investigational drugs in development for Hepatitis D.The IFN-λ-IFN-λR1-IL-10Rβ Complex Reveals Structural Features Underlying Type III IFN Functional Plasticity.Cost-Effectiveness of Peg-Interferon, Interferon and Oral Nucleoside Analogues in the Treatment of Chronic Hepatitis B and D Infections in China.A targeted functional RNA interference screen uncovers glypican 5 as an entry factor for hepatitis B and D viruses.High prevalence of hepatitis delta virus in Cameroon
P2860
Q26775635-083E3720-59F3-4A9A-AD0A-C97CA8242579Q26849602-986491B2-041E-4D0F-A09B-C358B8197603Q28068209-A150BB6C-E95D-4322-8002-A0567F8E98CBQ34404998-0C88D8BE-D99C-4D4A-8786-452275A91932Q35526264-7B7FCE97-23BB-40E6-B509-2B279F4081B4Q35778059-F62C5E01-6A13-42E2-895D-7C42D3774626Q37182821-C9C9860D-C86A-486B-A1C8-B6F8E1FDD1EFQ37252908-9AA4E167-0C01-40FC-AD01-404C3FCFA23DQ37581726-ED39D565-3E39-4E31-9A2D-0E1F7F99483FQ38357110-2E93F06D-15DD-4669-9180-8AC917363E53Q38562544-DAE43F09-DB4D-41EA-B095-C754AD98DA1EQ38685615-2D8BDD68-DB64-4CED-B42F-826B255EEEADQ38775846-CA7A9C79-F150-4005-A722-DB3C71551B7DQ39316007-2DA4ABD6-BC5B-4B13-9C1B-C32C1D481156Q40042818-488F4BEA-F71B-4B39-B0A8-F07D170792EFQ40113645-07814B6F-10C7-4878-8E66-3CA0D527709CQ40280003-4715EB4E-990E-491A-AD49-28224C81B7D9Q40679543-12F24824-E511-4562-9F56-764552C289D8Q41082130-63F9CB2E-9422-49A0-AF89-696718EA3D3BQ56930136-F1CCEE57-3AE7-472C-9591-C02F51601337
P2860
Chronic hepatitis D at a standstill: where do we go from here?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Chronic hepatitis D at a standstill: where do we go from here?
@en
Chronic hepatitis D at a standstill: where do we go from here?
@nl
type
label
Chronic hepatitis D at a standstill: where do we go from here?
@en
Chronic hepatitis D at a standstill: where do we go from here?
@nl
prefLabel
Chronic hepatitis D at a standstill: where do we go from here?
@en
Chronic hepatitis D at a standstill: where do we go from here?
@nl
P2860
P1476
Chronic hepatitis D at a standstill: where do we go from here?
@en
P2093
Alessia Ciancio
Mario Rizzetto
P2860
P2888
P356
10.1038/NRGASTRO.2013.164
P407
P577
2013-09-10T00:00:00Z